Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
March 12, 2025 07:30 ET
|
Mesoblast Limited
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive...
Mesoblast Added to S&P/ASX 200 INDEX
March 06, 2025 18:54 ET
|
Mesoblast Limited
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the...
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
February 26, 2025 17:30 ET
|
Mesoblast Limited
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and...
Mesoblast Financial Results and Corporate Update Webcast
February 25, 2025 18:13 ET
|
Mesoblast Limited
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Dr. Gregory George MD PhD Joins Mesoblast Board
February 23, 2025 18:33 ET
|
Mesoblast Limited
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed...
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
February 13, 2025 18:37 ET
|
Mesoblast Limited
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently...
Ryoncil® Commercial Launch Update and Product Pipeline
January 30, 2025 19:11 ET
|
Mesoblast Limited
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
January 30, 2025 18:20 ET
|
Mesoblast Limited
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024 19:08 ET
|
Mesoblast Limited
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers,...
Mesoblast to be Added to Nasdaq Biotechnology Index
December 18, 2024 07:30 ET
|
Mesoblast Limited
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition...